Profile data is unavailable for this security.
About the company
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
- Revenue in USD (TTM)0.00
- Net income in USD-53.37m
- Incorporated2011
- Employees54.00
- LocationLeap Therapeutics Inc47 Thorndike St Ste B1-1CAMBRIDGE 02141-1799United StatesUSA
- Phone+1 (617) 252-4343
- Fax+1 (302) 636-5454
- Websitehttps://www.leaptx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genelux Corp | 8.00k | -25.78m | 87.73m | 23.00 | -- | 4.56 | -- | 10,965.98 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Ikena Oncology Inc | 3.85m | -70.09m | 87.83m | 34.00 | -- | 0.5654 | -- | 22.82 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
SCYNEXIS Inc | 140.39m | 101.33m | 88.03m | 29.00 | 1.16 | 1.19 | -- | 0.627 | 2.01 | 2.01 | 2.89 | 1.96 | 1.49 | -- | 136.30 | 4,840,862.00 | 107.48 | -30.02 | 175.37 | -36.35 | 88.97 | -- | 72.18 | -86.76 | -- | 193.81 | 0.1433 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
PMV Pharmaceuticals Inc | 0.00 | -65.10m | 89.00m | 63.00 | -- | 0.4185 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Relmada Therapeutics Inc | 0.00 | -94.30m | 89.32m | 20.00 | -- | 1.24 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Beyondspring Inc | 1.75m | -21.03m | 89.38m | 35.00 | -- | -- | -- | 51.04 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Vor Biopharma Inc | 0.00 | -120.23m | 89.42m | 168.00 | -- | 0.7263 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Allovir Inc | 0.00 | -179.53m | 89.71m | 112.00 | -- | 0.7441 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 89.79m | 15.00 | 8.88 | 0.5374 | 8.59 | 133.22 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Leap Therapeutics Inc | 0.00 | -53.37m | 89.92m | 54.00 | -- | 1.27 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Precision BioSciences Inc | 57.53m | -19.99m | 90.10m | 109.00 | -- | 2.42 | -- | 1.57 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 92.57m | 81.00 | -- | 0.9562 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 92.64m | 35.00 | 410.98 | 365.90 | -- | 37.15 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Baker Bros. Advisors LPas of 31 Mar 2024 | 1.17m | 4.58% |
Rock Springs Capital Management LPas of 31 Mar 2024 | 911.94k | 3.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 856.10k | 3.34% |
Citadel Advisors LLCas of 31 Mar 2024 | 711.32k | 2.78% |
Balyasny Asset Management LPas of 31 Mar 2024 | 670.54k | 2.62% |
Adage Capital Management LPas of 31 Mar 2024 | 480.00k | 1.88% |
683 Capital Management LLCas of 31 Mar 2024 | 450.00k | 1.76% |
Simplify Asset Management, Inc.as of 31 Mar 2024 | 375.98k | 1.47% |
Acuta Capital Partners LLCas of 31 Mar 2024 | 354.17k | 1.38% |
Acadian Asset Management LLCas of 31 Mar 2024 | 282.41k | 1.10% |